Proactive Investors - Run By Investors For Investors

Alliance Pharma receives Irish green light for nausea drug

Xonvea will be prescribed to women who are sick during pregnancy where conservative treatment has failed
pregnant woman
The drug will go on sale in Ireland towards the end of the year

Alliance Pharma PLC (LON:APH) has confirmed its morning sickness treatment Xonvea has received marketing approval in Ireland.

This paves the way for the first launch of the product outside the UK. The company to start selling the drug in the Republic in the final quarter of this year.

As in the UK, it will be prescribed for nausea and vomiting in pregnancy where conservative management has failed.

The condition affects 70-80% of women during pregnancy in Ireland, mirroring what is seen in Britain.

View full APH profile View Profile

Alliance Pharma PLC Timeline

Newswire
January 21 2019

Related Articles

1550762209_shutterstock_291998651.jpg
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
blood
June 21 2019
Belgium-based company’s Nu.Q test screens for colorectal and prostate cancers, and may have the potential to detect ovarian disease endometriosis
Alliance
April 05 2019
Chief executive Peter Butterfield said the company has started 2019 well-positioned for growth after a strong performance in 2018.
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use